Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistCholrem Pty Ltd, a pharmaceutical company operating under the trade names Cholrem and Cholrem Pharmaceuticals, received an FDA Warning Letter on July 9, 2024, regarding drug products. While the specific violations are not detailed in the available metadata, the letter indicates regulatory concerns within FDA's drug oversight authority. Without access to the full warning letter text, the precise nature of the compliance issues cannot be determined from this metadata alone.